Cargando…

The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota

BACKGROUND: Chronic obstructive pulmonary disease (COPD), a prevalent, progressive respiratory disease, has become the third leading cause of death globally. Increasing evidence suggests that intestinal and pulmonary microbiota dysbiosis is associated with COPD. Researchers have shown that T helper...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Yu, He, Tiantian, Wu, Di, Tong, Jiabing, Zhu, Jie, Li, Zegeng, Dong, Jingcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210581/
https://www.ncbi.nlm.nih.gov/pubmed/35729584
http://dx.doi.org/10.1186/s12967-022-03481-w
_version_ 1784730187343069184
author Jia, Yu
He, Tiantian
Wu, Di
Tong, Jiabing
Zhu, Jie
Li, Zegeng
Dong, Jingcheng
author_facet Jia, Yu
He, Tiantian
Wu, Di
Tong, Jiabing
Zhu, Jie
Li, Zegeng
Dong, Jingcheng
author_sort Jia, Yu
collection PubMed
description BACKGROUND: Chronic obstructive pulmonary disease (COPD), a prevalent, progressive respiratory disease, has become the third leading cause of death globally. Increasing evidence suggests that intestinal and pulmonary microbiota dysbiosis is associated with COPD. Researchers have shown that T helper (Th) 17/regulatory T (Treg) imbalance is involved in COPD. Qibai Pingfei Capsule (QBPF) is a traditional Chinese medicine used to treat COPD clinically in China. However, the effects of QBPF intervention on the Th17/Treg balance and microbiota in the gut and lung are still poorly understood. METHODS: This study divided the rats into three groups (n = 8): control, model, and QBPF group. After establishing the model of COPD for four weeks and administering of QBPF for two weeks, Th17 cells, Treg cells, their associated cytokines, transcription factors, and intestinal and pulmonary microbiota of rats were analyzed. Furthermore, the correlations between intestinal and pulmonary microbiota and between bacterial genera and pulmonary function and immune function were measured. RESULTS: The results revealed that QBPF could improve pulmonary function and contribute to the new balance of Th17/Treg in COPD rats. Meanwhile, QBPF treatment could regulate the composition of intestinal and pulmonary microbiota and improve community structure in COPD rats, suppressing the relative abundance of Coprococcus_2, Prevotella_9, and Blautia in the gut and Mycoplasma in the lung, but accumulating the relative abundance of Prevotellaceae_UCG_003 in the gut and Rikenellaceae_RC9_gut_group in the lung. Additionally, gut–lung axis was confirmed by the significant correlations between the intestinal and pulmonary microbiota. Functional analysis of microbiota showed amino acid metabolism was altered in COPD rats in the gut and lung. Spearman correlation analysis further enriched the relationship between the microbiota in the gut and lung and pulmonary function and immune function in COPD model rats. CONCLUSIONS: Our study indicated that the therapeutic effects of QBPF may be achieved by maintaining the immune cell balance and regulating the gut-lung axis microbiota, providing references to explore the potential biomarkers of COPD and the possible mechanism of QBPF to treat COPD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03481-w.
format Online
Article
Text
id pubmed-9210581
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92105812022-06-22 The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota Jia, Yu He, Tiantian Wu, Di Tong, Jiabing Zhu, Jie Li, Zegeng Dong, Jingcheng J Transl Med Research BACKGROUND: Chronic obstructive pulmonary disease (COPD), a prevalent, progressive respiratory disease, has become the third leading cause of death globally. Increasing evidence suggests that intestinal and pulmonary microbiota dysbiosis is associated with COPD. Researchers have shown that T helper (Th) 17/regulatory T (Treg) imbalance is involved in COPD. Qibai Pingfei Capsule (QBPF) is a traditional Chinese medicine used to treat COPD clinically in China. However, the effects of QBPF intervention on the Th17/Treg balance and microbiota in the gut and lung are still poorly understood. METHODS: This study divided the rats into three groups (n = 8): control, model, and QBPF group. After establishing the model of COPD for four weeks and administering of QBPF for two weeks, Th17 cells, Treg cells, their associated cytokines, transcription factors, and intestinal and pulmonary microbiota of rats were analyzed. Furthermore, the correlations between intestinal and pulmonary microbiota and between bacterial genera and pulmonary function and immune function were measured. RESULTS: The results revealed that QBPF could improve pulmonary function and contribute to the new balance of Th17/Treg in COPD rats. Meanwhile, QBPF treatment could regulate the composition of intestinal and pulmonary microbiota and improve community structure in COPD rats, suppressing the relative abundance of Coprococcus_2, Prevotella_9, and Blautia in the gut and Mycoplasma in the lung, but accumulating the relative abundance of Prevotellaceae_UCG_003 in the gut and Rikenellaceae_RC9_gut_group in the lung. Additionally, gut–lung axis was confirmed by the significant correlations between the intestinal and pulmonary microbiota. Functional analysis of microbiota showed amino acid metabolism was altered in COPD rats in the gut and lung. Spearman correlation analysis further enriched the relationship between the microbiota in the gut and lung and pulmonary function and immune function in COPD model rats. CONCLUSIONS: Our study indicated that the therapeutic effects of QBPF may be achieved by maintaining the immune cell balance and regulating the gut-lung axis microbiota, providing references to explore the potential biomarkers of COPD and the possible mechanism of QBPF to treat COPD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03481-w. BioMed Central 2022-06-21 /pmc/articles/PMC9210581/ /pubmed/35729584 http://dx.doi.org/10.1186/s12967-022-03481-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jia, Yu
He, Tiantian
Wu, Di
Tong, Jiabing
Zhu, Jie
Li, Zegeng
Dong, Jingcheng
The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota
title The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota
title_full The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota
title_fullStr The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota
title_full_unstemmed The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota
title_short The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota
title_sort treatment of qibai pingfei capsule on chronic obstructive pulmonary disease may be mediated by th17/treg balance and gut-lung axis microbiota
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210581/
https://www.ncbi.nlm.nih.gov/pubmed/35729584
http://dx.doi.org/10.1186/s12967-022-03481-w
work_keys_str_mv AT jiayu thetreatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT hetiantian thetreatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT wudi thetreatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT tongjiabing thetreatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT zhujie thetreatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT lizegeng thetreatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT dongjingcheng thetreatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT jiayu treatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT hetiantian treatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT wudi treatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT tongjiabing treatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT zhujie treatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT lizegeng treatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota
AT dongjingcheng treatmentofqibaipingfeicapsuleonchronicobstructivepulmonarydiseasemaybemediatedbyth17tregbalanceandgutlungaxismicrobiota